Open Access

Botulinum toxin related research in maxillofacial plastic and reconstructive surgery

Maxillofacial Plastic and Reconstructive Surgery201638:34

DOI: 10.1186/s40902-016-0080-2

Received: 20 August 2016

Accepted: 20 August 2016

Published: 5 September 2016

Botulism caused by food poisoning was characterized by mydriasis and skeletal muscle paralysis, which was first described by Justinus Kerner in 1820 [1]. The cause of botulism was botulinum neurotoxin produced by anaerobic, spore-forming bacteria of the genus Clostridium [2]. Botulinum toxin (BTX) became to be the first medically applied toxin. The first clinical use of BTX was reported concerning the treatment of strabismus in ophthalmologic field in 1980 [3]. Nine years later, the Food and Drug Administration (FDA) approved the clinical application of BTX for adult strabismus and blepharospasm [4]. BTX inhibits acetylcholine exocytosis at neuromuscular junction of the preganglionic sympathetic/parasympathetic nerve fibers and postganglionic parasympathetic nerves [5].

BTX is clinically administrated to treat various therapeutic indications: strabismus, migraine, bladder dystonia, hyperhidrosis, cervical dystonia, upper limb spasticity, voice abnormality, chronic pain management, and cerebral palsy [6]. Recently, the most popular indication in public is the control of facial wrinkle [7]. In oral and maxillofacial surgery field, BTX injection is applied not only for cosmetic purposes such as glabella line correction, platysma band correction, or gummy smile but also for therapeutic indications such as masseteric or temporalis muscle hypertrophy [810], temporomandibular joint disorders [9, 11], salivary gland secretory disorders (including sialorrhea, Frey syndrome) [12], hypertrophic scars [13], facial pains [14], and facial paralysis [15, 16]. Especially in dental field, it had been reported that BTX improved painful symptoms as high as 90 % of temporomandibular joint disorders related to masticatory muscles [17]. In cosmetic purpose in dental field, excessive gingival exposure during smile or asymmetric smile can be corrected by the BTX injection into peri-oral muscles [18, 19]. Therefore, even though BTX treatment had been historically dermatologists and neurologists’ jurisdiction, it now became the dentists’ jurisdiction because the training and scientific knowledge covers the entire head and neck region [19].

However, there are a number of complications associated with the BTX injection especially related with the accidental overdose. According to the previous report, there are various local and systemic side effects after BTX injection. Pain, edema, headache, and bruising would be the common loco-regional side effects, and nausea, fatigue, headache, facial pain, flu-like symptoms, anxiety, and itching can appear as systemic side effects after BTX administration [1, 20]. In 2005, it was reported that the adverse event reported to the FDA (Dec 1989~May 2003) after therapeutic and cosmetic use of BTX was 1437 cases. Among these, 217 serious adverse events were reported including 28 reported deaths; respiratory arrest (n = 6), myocardial infarction (n = 5), cerebrovascular accident (n = 3), pulmonary embolism (n = 2), and others (n = 3) [21]. All of them were related to therapeutic application rather than cosmetic purpose of the BTX.

Even though there are numerous publications reporting successful outcomes after BTX application, there are only a few scientific reports with high level of scientific evidence. Because the clinical research had not been carried out with randomized, controlled, blinded settings, more clinical and experimental research should be encouraged. Clinical research need to be carried out more tightly under controlled condition with a prospective, randomized design rather than demonstration of successful case series. At the same time, to overcome fundamental limitations of the BTX, the basic research is needed to advance and improve the clinical application of BTX.

Declarations

Competing interests

The author declares that he has no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

(1)
Department of Oral and Maxillofacial Surgery, School of Dentistry, Kyungpook National University

References

  1. Lu DW, Lippitz J (2009) Complications of botulinum neurotoxin. Dis Mon 55:198–211View ArticlePubMedGoogle Scholar
  2. Popoff MR, Bouvet P (2013) Genetic characteristics of toxigenic Clostridia and toxin gene evolution. Toxicon 75:63–89View ArticlePubMedGoogle Scholar
  3. Scott AB (1980) Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 87:1044–1049View ArticlePubMedGoogle Scholar
  4. Scott AB (2004) Development of botulinum toxin therapy. Dermatol Clin 22:131–133View ArticlePubMedGoogle Scholar
  5. Khanna S, Jain S (2006) Botox: the poison that heals. Int Dent J 56:356–358View ArticlePubMedGoogle Scholar
  6. de Maio M (2008) Therapeutic uses of botulinum toxin: from facial palsy to autonomic disorders. Expert Opin Biol Ther 8:791–798View ArticlePubMedGoogle Scholar
  7. Jaspers GW, Pijpe J, Jansma J (2011) The use of botulinum toxin type A in cosmetic facial procedures. Int J Oral Maxillofac Surg 40:127–133View ArticlePubMedGoogle Scholar
  8. Ihde SK, Konstantinovic VS (2007) The therapeutic use of botulinum toxin in cervical and maxillofacial conditions: an evidence-based review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104:e1–e11View ArticlePubMedGoogle Scholar
  9. Jeong CH, Ryu JY, Lee WY, Kim HM (2015) Simultaneous surgery for subcondylar fracture and prominent angle of the mandible. Maxillofac Plast Reconstr Surg 37:26View ArticlePubMedPubMed CentralGoogle Scholar
  10. Lee CJ, Kim SG, Kim YJ, Han JY, Choi SH, Lee SI (2007) Electrophysiologic change and facial contour following botulinum toxin A injection in square faces. Plast Reconstr Surg 120:769–778View ArticlePubMedGoogle Scholar
  11. Kim HS, Yun PY, Kim YK (2016) A clinical evaluation of botulinum toxin-A injections in the temporomandibular disorder treatment. Maxillofac Plast Reconstr Surg 38:5View ArticlePubMedPubMed CentralGoogle Scholar
  12. Su JZ, Cai ZG, Yu GY (2015) Microvascular autologous submandibular gland transplantation in severe cases of keratoconjunctivitis sicca. Maxillofac Plast Reconstr Surg 37:5View ArticlePubMedPubMed CentralGoogle Scholar
  13. Zhang DZ, Liu XY, Xiao WL, Xu YX (2016) Botulinum toxin type A and the prevention of hypertrophic scars on the maxillofacial area and neck: a meta-analysis of randomized controlled trials. PLoS One 11:e0151627View ArticlePubMedPubMed CentralGoogle Scholar
  14. Srivastava S, Kharbanda S, Pal US, Shah V (2015) Applications of botulinum toxin in dentistry: a comprehensive review. Natl J Maxillofac Surg 6:152–159View ArticlePubMedPubMed CentralGoogle Scholar
  15. Garcia RM, Hadlock TA, Klebuc MJ, Simpson RL, Zenn MR, Marcus JR. Contemporary solutions for the treatment of facial nerve paralysis (2015) Plast Reconstr Surg 135:1025e-1046e. doi:10.1097/PRS.0000000000001273.
  16. Sinclair CF, Gurey LE, Blitzer A (2013) Oromandibular dystonia: long-term management with botulinum toxin. Laryngoscope 123:3078–3083View ArticlePubMedGoogle Scholar
  17. Bhogal PS, Hutton A, Monaghan A (2006) A review of the current uses of Botox for dentally-related procedures. Dent Update 33:165–168PubMedGoogle Scholar
  18. Niamtu J 3rd (2003) Botulinum toxin A: a review of 1,085 oral and maxillofacial patient treatments. J Oral Maxillofac Surg 61:317–324View ArticlePubMedGoogle Scholar
  19. Hoque A, McAndrew M (2009) Use of botulinum toxin in dentistry. N Y State Dent J 75:52–55PubMedGoogle Scholar
  20. Archana MS (2016) Toxin yet not toxic: botulinum toxin in dentistry. Saudi Dent J 28:63–69View ArticlePubMedGoogle Scholar
  21. Cote TR, Mohan AK, Polder JA, Walton MK, Braun MM (2005) Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 53:407–415View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2016